Journal of Clinical Endocrinology & Metabolism, Vol 79, 165-170, Copyright © 1994 by Endocrine Society

ARTICLES

Treatment of malignancy-associated hypercalcemia with YM175, a new bisphosphonate: elevated threshold for parathyroid hormone secretion in hypercalcemic patients

S Fukumoto, T Matsumoto, K Takebe, T Onaya, S Eto, H Nawata and E Ogata
Fourth Department of Internal Medicine, University of Tokyo School of Medicine, Japan.

The effect of a new third generation bisphosphonate, YM175 (cycloheptylamino-methylene bisphosphonate), on serum calcium (Ca) and intact PTH levels was examined in 79 malignancy-associated hypercalcemia patients with serum Ca levels higher than 2.75 mmol/L. A single infusion of 2.5, 5, and 10 mg YM175 reduced serum Ca levels in a dose-dependent manner. YM175 was about 6 times more potent than 3-amino- hydroxypropylidene-1,1-bisphosphonate. Among 23 patients treated with 10 mg YM175, serum Ca decreased by more than 0.5 mmol/L in 20 patients and was normalized in 11 patients. Serum intact PTH was subnormal in all of these patients before treatment and remained subnormal in 12 patients (suppressed PTH group), but was elevated to normal or high levels after treatment in the remaining 11 patients (responsive PTH group). Serum Ca was significantly higher throughout the study period in the suppressed PTH group, and mean serum Ca at the nadir did not decrease below 2.90 mmol/L in this group. However, the rate or magnitude of reduction in serum Ca was not different in the two groups. Polynomial regression analysis revealed that the threshold of serum Ca for PTH secretion was elevated to 2.75 mmol/L in the responsive PTH group, whereas it was about the upper limit of normal when both groups were combined (2.59 mmol/L). Furthermore, in the responsive PTH group, the threshold for PTH secretion during the decreasing serum Ca phase (days 4 and 6) was higher than that during the increasing serum Ca phase (days 10 and 14). The changes in the threshold for PTH secretion were also observed in patients treated with lower doses of YM175. These results demonstrate that YM175 is one of the most potent currently available bisphosphonates, and that the threshold for PTH secretion is elevated in at least some malignancy-associated hypercalcemia patients. In addition, there appears to be a difference in the threshold for PTH secretion between the decreasing and increasing serum Ca phases similar to the previously reported hysteresis phenomenon.

This article has been cited by other articles:

				Y Saunders, J R Ross, K E Broadley, P M Edmonds, and S Patel Systematic review of bisphosphonates for hypercalcaemia of malignancy Palliative Medicine, July 1, 2004; 18(5): 418 - 431. [Abstract] [PDF]

				L. S. Blevins Jr., J. H. Christy, M. Khajavi, and G. T. Tindall Outcomes of Therapy for Cushing's Disease due to Adrenocorticotropin-Secreting Pituitary Macroadenomas J. Clin. Endocrinol. Metab., January 1, 1998; 83(1): 63 - 67. [Abstract] [Full Text]